Zobrazeno 1 - 10
of 45
pro vyhledávání: '"D I Yudin"'
Autor:
K K Laktionov, E V Reutova, L A Nelyubina, M Yu Pitkevich, M A Okruzhnova, M S Ardzinba, D I Yudin, I A Demidova, A R Zaretsky
Publikováno v:
Современная онкология, Vol 20, Iss 2, Pp 50-54 (2018)
Targeted therapy has opened a new era in treatment of patients with non-small-cell lung cancer associated with mutations of the epidermal growth factor receptor (EGFR) gene. However, most patients after starting targeted therapy develop progression w
Externí odkaz:
https://doaj.org/article/f71ef2be1a2441fe85d5f8f7b19b326f
Autor:
I. A. Dzhanyan, M. S. Novruzbekov, O. D. Olisov, D. I. Yudin, V. S. Rudakov, E. Yu. Antonova, I. V. Savchenko, I. V. Pogrebnyakov, V. V. Breder, M. Yu. Pitkevich
Publikováno v:
Вестник медицинского института «Реавиз»: Реабилитация, врач и здоровье, Vol 13, Iss 4, Pp 162-168 (2023)
Hepatocellular carcinoma (HCC) is the third cause of cancer-related mortality worldwide, accounting for more than 800,000 deaths annually. Surgical removal of the neoplasm remains the most effective treatment option. Partial liver resection is an ade
Externí odkaz:
https://doaj.org/article/02e2772863cf41b8b0e78f9f587502c8
Publikováno v:
Сибирский онкологический журнал, Vol 22, Iss 2, Pp 56-64 (2023)
Aim of the study: to evaluate prognostic value of baseline lung immune prognostic index (LIPI) and its modification (mLIPI) for metastatic non-small cell lung cancer (mNSCLC) patients treated with immune checkpoint inhibitors (ICI).Material and metho
Externí odkaz:
https://doaj.org/article/711ddfebc8424d3c82687bb8d30323b2
Autor:
D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, V. V. Breder, M. S. Ardzinba, E. V. Reutova, O. I. Borisova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 18-24 (2021)
Introduction. Lung cancer remains the one of the most common and fatal cancers in the world. For a long time, chemotherapy was the only treatment option for metastatic lung cancer. Currently, immunotherapy became the one of the preferred options of t
Externí odkaz:
https://doaj.org/article/2147954dcc9547a6a6fbf739228a60c2
Publikováno v:
Медицинский совет, Vol 0, Iss 4S, Pp 108-113 (2021)
Checkpoint inhibitors, as well as their combinations, are increasingly included in the daily practice of the oncologist. However, given the mechanism of action, its use may be associated with immune side effects that can complicate the clinical cours
Externí odkaz:
https://doaj.org/article/c12721c2595741ba83208befcb7932e0
Autor:
E. S. Denisova, K. K. Laktionov, T. N. Borisova, Merab. S. Ardzinba, A. A. Fedorova, D. I. Yudin, S. S. Magamedova, Milada A. Ardzinba
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 188-193 (2020)
The abscopal effect was described more than 50 years ago and is a phenomenon in which radiation therapy promotes the regression of metastatic foci remote from the site of radiation. For decades, this effect has been described as a rare, unexplained p
Externí odkaz:
https://doaj.org/article/1c63e70f6a7d4b39a81faaa91607768d
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 194-198 (2020)
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EG
Externí odkaz:
https://doaj.org/article/d1c4770fc86945a580bed36e07f1feba
Autor:
D. I. Yudin, K. K. Laktionov, K. A. Sarantseva, O. I. Borisova, V. V. Breder, E. V. Reutova, M. F. Beloyartseva, S. Yu. Kruteleva, I. A. Dzhanyan
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 16-24 (2020)
Recently immune checkpoint inhibitors amazingly changed the landscape of cancer therapy worldwide. The number of immune checkpoint molecules in clinical practice is constantly increasing. There are some monoclonal antibodies recently registered in th
Externí odkaz:
https://doaj.org/article/87179a43c93546bfb40f6596a9ef6212
Autor:
E. S. Denisova, M. S. Ardzinba, K. K. Laktionov, D. I. Yudin, K. A. Sarantseva, G. V. Shcherbakova, N. V. Marinichenko
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 258-264 (2020)
Immunotherapy is the most promising method in the treatment of lung cancer, especially in connection with the rapidly growing development of monoclonal antibodies aimed at inhibiting immune checkpoints: anti-CTLA-4, anti-PD-1, anti-PD-L1. Classic imm
Externí odkaz:
https://doaj.org/article/acbaa47445df43a3ba3ace856ed6092f
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 16-21 (2019)
Non-small cell lung cancer (NSCLC) is the leading cause of death from cancer worldwide. Despite the success over recent years in the treatment of NSCLC it has not yet been able to achieve good long-term survival. The development of immune checkpoint
Externí odkaz:
https://doaj.org/article/3b3f1f551d624a68b91294dfbe814486